fluorouracil has been researched along with Lassitude in 111 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Excerpt | Relevance | Reference |
---|---|---|
"The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 9.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
"Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects." | 9.17 | Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013) |
"This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 9.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
"We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab." | 9.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
"The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 9.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
"To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 9.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
"Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 9.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
"Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 9.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
"This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 9.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
"The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 9.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
" This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer." | 9.12 | Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). ( Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006) |
"The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 9.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 9.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
"5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients." | 9.08 | Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. ( Hande, KR; Johnson, DH; Paul, D, 1997) |
"Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 9.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
" We used a mouse model to examine the benefits of quercetin on CIF as measured by voluntary wheel running activity and sought to determine whether quercetin may be associated with a decrease in inflammation and/or anemia." | 7.80 | Dietary quercetin reduces chemotherapy-induced fatigue in mice. ( Davis, JM; Mahoney, SE; McClellan, JL; Murphy, EA; Pena, MM, 2014) |
"To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 7.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 7.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
"Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 7.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
"The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 7.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
"The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) plus bevacizumab, and folinic acid, 5-FU and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer." | 5.22 | Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). ( Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T, 2016) |
"The aim of this multicenter, open-label, randomized phase II trial was to evaluate the efficacy of a dose-dense capecitabine and oxaliplatin (XELOX) regimen in patients with metastatic colorectal cancer (mCRC) for whom reintroduction of oxaliplatin had been planned as a third- or later-line regimen." | 5.22 | Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). ( Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y, 2016) |
"The purpose of this phase I study was to determine the safety, toxicity, maximum tolerated dose, and pharmacokinetics of capecitabine when administered concurrently with radiotherapy in patients with localised, inoperable pancreatic adenocarcinoma." | 5.19 | A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. ( Crellin, A; Evans, TR; Harden, S; James, A; Lumsden, GR; McDonald, AC; Morrison, R; Paul, J; Roxburgh, P; Sweeting, L, 2014) |
"The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 5.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
"The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 5.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
"Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects." | 5.17 | Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013) |
"Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer." | 5.17 | Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013) |
"We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab." | 5.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
"This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 5.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
"To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 5.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
"Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 5.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
"Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 5.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
"This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 5.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
"The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 5.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
"The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 5.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
" This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer." | 5.12 | Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). ( Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006) |
"A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer." | 5.12 | Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006) |
"Ninety patients with breast cancer were included; 70 patients received single agent paclitaxel either weekly or every 3 weeks and 20 received FAC (5-FU, doxorubicin, cyclophosphamide) chemotherapy." | 5.11 | Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. ( Arun, B; Booser, D; Bruera, E; Cleeland, CS; Fritsche, HA; Hortobagyi, GN; Ibrahim, N; Lara, J; Martinez, MM; Mendoza, TR; Pusztai, L; Reuben, JM; Rivera, E; Royce, M; Syed, A; Valero, V; Willey, JS, 2004) |
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 5.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
"Pegylated liposomal doxorubicin-based combination chemotherapy with capecitabine or gemcitabine was not effective as salvage therapy in advanced hepatocellular carcinoma." | 5.11 | Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. ( Bai, LY; Chen, PM; Poh, SB, 2005) |
" The purpose of this study was to examine the relationship between exercise and fatigue over the first three cycles of chemotherapy in women receiving either cyclophosphamide, methotrexate, and fluorouracil (CMF) or doxorubicin and cyclophosphamide (AC) for breast cancer." | 5.09 | Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. ( Gao, R; King, ME; Mori, M; Nail, LM; Schwartz, AL, 2001) |
"5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients." | 5.08 | Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. ( Hande, KR; Johnson, DH; Paul, D, 1997) |
"Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 5.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
" Female sex, breast cancer diagnosis, capecitabine monotherapy, and severe HFS were found to be associated with dose reductions (p-values < 0." | 4.12 | Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes. ( Barton, DL; Chittiprolu, A; Cho, Y; Gong, Y; Harden, K; Harris, MR; Jiang, Y; Mason, M; Zhang, X, 2022) |
" We used a mouse model to examine the benefits of quercetin on CIF as measured by voluntary wheel running activity and sought to determine whether quercetin may be associated with a decrease in inflammation and/or anemia." | 3.80 | Dietary quercetin reduces chemotherapy-induced fatigue in mice. ( Davis, JM; Mahoney, SE; McClellan, JL; Murphy, EA; Pena, MM, 2014) |
"To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 3.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
"Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 3.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 3.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
"We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
"The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 3.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
"Multiple studies have shown that leucovorin-fluorouracil regimens are modestly superior to fluorouracil alone in the treatment of advanced colorectal cancer." | 3.69 | Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine. ( DeLap, RJ; Marshall, JL; Richmond, E, 1996) |
" Patient characteristics were evaluated with multiple regression analyses for survival outcomes, using the Cox proportional hazard model and linear regression analyses for the worst grade of adverse events." | 3.11 | Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. ( Amagai, K; Bando, Y; Denda, T; Endo, S; Hatachi, Y; Hyodo, I; Ikezawa, K; Ishida, H; Kobayashi, K; Kuramochi, H; Morimoto, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Sakai, Y; Sato, M; Shimada, M; Tsuji, A; Yamamoto, Y, 2022) |
"This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6)." | 2.77 | A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. ( Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J, 2012) |
"Patients with T3/T4 or node positive rectal cancer were treated with capecitabine 1,000 mg/m(2) twice daily (BID) days 1-14, and irinotecan 200 mg/m(2) on day 1 every 21 days for 2 cycles, followed by capecitabine 825 mg/m(2) BID days 1-5 per week with concurrent radiotherapy 50." | 2.77 | Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. ( Bufill, J; Burns, M; Cardenes, H; Chiorean, EG; Clark, R; Coleman, N; Curie, C; Hinkle, DT; LeBlanc, J; Loehrer, PJ; Robb, B; Sanghani, S; Schiel, MA; Tong, Y; Yu, M, 2012) |
"Patients with stage II and III esophageal cancer were enrolled." | 2.77 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012) |
"The primary objective of this Phase I study was to assess the safety and tolerability of the vascular endothelial growth factor signalling inhibitor cediranib in combination with cisplatin plus an oral fluoropyrimidine, in Japanese patients with previously untreated advanced gastric cancer." | 2.77 | Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. ( Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012) |
" Most frequent drug-related adverse events were hand-foot skin reaction (HFSR, 89%), diarrhea (71%), and fatigue (69%)." | 2.76 | Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. ( Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N, 2011) |
"5, or 50 mg) was administered orally once daily on three dosing schedules: 4 weeks on treatment, 2 weeks off treatment (Schedule 4/2); 2 weeks on treatment, 1 week off treatment (Schedule 2/1); and continuous daily dosing (CDD schedule)." | 2.75 | A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. ( Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF, 2010) |
"Fifty-four patients with T3/T4/N+ rectal cancers were treated on a Phase II trial using preoperative capecitabine and concomitant boost radiotherapy." | 2.74 | Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. ( Cleeland, CS; Crane, CH; Das, P; Delclos, ME; Hundal, M; Janjan, NA; Krishnan, S; Lin, EH; Mendoza, TR; Park, HC; Vadhan-Raj, S; Wang, XS; Zhang, Y, 2009) |
" Follow-up for potential delayed adverse effects and efficacy is ongoing." | 2.74 | Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. ( Allegra, CJ; Atkins, JN; Azar, CA; Chu, L; Colangelo, LH; Fehrenbacher, L; Goldberg, RM; Lopa, SH; O'Connell, MJ; O'Reilly, S; Petrelli, NJ; Seay, TE; Sharif, S; Wolmark, N; Yothers, G, 2009) |
"Oral capecitabine was administered twice daily continuously with weekend breaks, in patients with advanced solid tumours refractory to standard therapy." | 2.73 | Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. ( Boumba, VA; Fountzilas, G; Golfinopoulos, V; Marselos, M; Nikiforidis, L; Nikolaidou, M; Pappas, P; Pavlidis, N; Pentheroudakis, G; Siarabi, O; Tzamakou, E; Vougiouklakis, T, 2007) |
" Leucovorin (LV) dosage was fixed at 500 mg/m(2)." | 2.71 | Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. ( Fleming, GF; Hong, AM; Meyerson, A; Ratain, MJ; Schilsky, RL; Schumm, LP; Vogelzang, NJ, 2003) |
" A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer." | 2.71 | A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. ( Bisset, D; Boyle, D; Camboni, G; Cassidy, J; Edwards, C; Gourley, C; Jodrell, D; Samuel, L; Young, A, 2004) |
", Carlsbad, CA) when administered in combination with 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.70 | Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. ( Dorr, FA; Geary, RS; Holmlund, JT; Kindler, HL; Kunkel, K; Mani, S; Ratain, MJ; Rudin, CM, 2002) |
"Nine patients with colorectal cancer and one with gastric cancer had partial or minor responses." | 2.70 | A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. ( Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA, 2002) |
"From a randomized study in high-risk breast cancer patients on the efficacy of high-dose versus standard-dose adjuvant chemotherapy, late effects on cognitive functioning were analyzed by neuropsychological tests." | 2.70 | Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. ( Boogerd, W; Hamburger, HL; Muller, MJ; Schagen, SB; van Dam, FS, 2001) |
"Fatigue was a frequent side-effect during both PELF and docetaxel chemotherapy." | 2.70 | A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. ( Baldelli, AM; Barni, S; Casaretti, R; Cascinu, S; Catalano, G; Catalano, V; Comella, G; Frontini, L; Graziano, F; Labianca, R, 2001) |
" Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m(2)/week when combined with 5-fluorouracil (5-FU) at 200 mg/m(2)/day (Days 1-21) repeated every 4 weeks." | 2.70 | Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. ( Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ, 2001) |
"Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy." | 2.69 | Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). ( Coche-Dequeant, B; De Raucourt, D; Domenge, C; Hill, C; Lefebvre, JL; Luboinski, B; Marandas, P; Rhein, B; Sancho-Garnier, H; Stromboni-Luboinski, M; Wibault, P, 2000) |
" Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day." | 2.68 | Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996) |
"FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects." | 2.58 | The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. ( Fan, Z; Liu, B; Lu, T; Tong, H, 2018) |
"A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen." | 2.46 | Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. ( Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R, 2010) |
"Alopecia was observed in 60% of patients." | 1.62 | Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. ( Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A, 2021) |
"Patients with newly diagnosed advanced pancreatic cancer in Saskatchewan, Canada, from 2011 to 2016, who received FOLFIRINOX or GnP were assessed." | 1.51 | Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. ( Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A, 2019) |
"Fatigue is a common symptom in many diseases and disorders and can reduce quality of life, yet lacks an adequate pharmacological intervention." | 1.51 | Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays. ( Cullen, MJ; Dougherty, JP; Gershengorn, MC; Springer, DA, 2019) |
"Fatigue affects most cancer patients and has numerous potential causes, including cancer itself and cancer treatment." | 1.46 | Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue. ( Cullen, MJ; Dougherty, JP; Gershengorn, MC; Saligan, LN; Wolff, BS, 2017) |
"Depression was directly affected by fatigue (β=." | 1.43 | [Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer]. ( Lee, JR; Oh, PJ, 2016) |
"Twenty women undergoing CT for breast cancer completed the Pittsburgh Sleep Quality Index (PSQI) 1 h prior to a CT infusion." | 1.40 | Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. ( Arun, B; Cohen, L; Lam, CY; Ratcliff, CG; Valero, V, 2014) |
"3%); alteration and complete recovery (31%) or sustained deterioration (45%), possibly due to inadequate chronotherapy dosing and/or timing." | 1.40 | The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. ( Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA, 2014) |
"Fatigue is the most common symptom related to cytotoxic chemotherapeutic treatment of cancer." | 1.40 | A role for orexin in cytotoxic chemotherapy-induced fatigue. ( Marks, DL; Weymann, KB; Wood, LJ; Zhu, X, 2014) |
"Patients with metastatic colorectal cancer (n = 543) from an international phase 3 trial comparing FOLFOX2 with chronoFLO4 were categorized into 4 subgroups according to the occurrence of FWL or other clinically relevant toxicities during the initial 2 courses of chemotherapy." | 1.39 | Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Poncet, A; Smaaland, R; Spiegel, D; Tampellini, M; Tumolo, S, 2013) |
"Fatigue was assessed with the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)." | 1.38 | The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. ( Ancoli-Israel, S; Dimsdale, JE; Fiorentino, L; Liu, L; Mills, PJ; Natarajan, L; Parker, BA; Rissling, M; Sadler, GR, 2012) |
"A total of 88 patients treated for anal cancer at our institution between 1990 and 2006 were identified from our database." | 1.37 | Quality of life outcomes in patients with anal cancer after combined radiochemotherapy. ( Hägele, V; Mai, SK; Welzel, G; Wenz, F, 2011) |
"Fatigue was a prominent long-lasting symptom in these patients." | 1.37 | Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. ( Aarstad, AK; Aarstad, HJ; Hjermstad, MJ; Hurmuzlu, M; Viste, A, 2011) |
"Pretreatment distress and posttreatment nausea, vomiting, and fatigue were assessed at the 1st, 4th, 6th and last cycles of chemotherapy." | 1.34 | Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity. ( Jensen, AB; Johansson, A; Mehlsen, M; Paulsen, K; von der Maase, H; Zachariae, R, 2007) |
"The course of fatigue is significantly related to the type of chemotherapy." | 1.34 | [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst]. ( Abu-Saad, HH; Courtens, AM; de Jong, N; Kester, AD; Schouten, HC, 2007) |
"Grade 3/4 neutropenia was seen in 12 patients (60%), and neuropathy was observed in 11 patients (55%)." | 1.34 | Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. ( Kasai, M; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K, 2007) |
"With this knowledge breast cancer patients can be better informed about what they can expect." | 1.32 | Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. ( Abu-Saad, HH; Candel, MJ; Courtens, AM; de Jong, N; Schouten, HC, 2004) |
"Severe fatigue was defined as 7-10 on the "worst level of fatigue" item." | 1.31 | Fatigue during preoperative chemoradiation for resectable rectal cancer. ( Cleeland, CS; Crane, CH; Engstrom, MC; Guo, H; Janjan, NA; Johnson, BA; Mendoza, TR; Wang, XS, 2001) |
"Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer." | 1.28 | [Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients]. ( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (1.80) | 18.7374 |
1990's | 8 (7.21) | 18.2507 |
2000's | 40 (36.04) | 29.6817 |
2010's | 56 (50.45) | 24.3611 |
2020's | 5 (4.50) | 2.80 |
Authors | Studies |
---|---|
Goerling, U | 1 |
Gauler, T | 1 |
Dietz, A | 1 |
Grünwald, V | 1 |
Knipping, S | 1 |
Guntinas-Lichius, O | 1 |
Frickhofen, N | 1 |
Lindeman, HW | 1 |
Fietkau, R | 1 |
Haxel, B | 1 |
Große-Thie, C | 1 |
Maschmeyer, G | 1 |
Zipfel, M | 1 |
Martus, P | 1 |
Knoedler, M | 1 |
Keilholz, U | 1 |
Klinghammer, K | 1 |
Moriwaki, T | 1 |
Nishina, T | 1 |
Sakai, Y | 1 |
Yamamoto, Y | 2 |
Shimada, M | 1 |
Ishida, H | 1 |
Amagai, K | 1 |
Sato, M | 1 |
Endo, S | 1 |
Negoro, Y | 1 |
Kuramochi, H | 1 |
Denda, T | 1 |
Hatachi, Y | 1 |
Ikezawa, K | 1 |
Nakajima, G | 1 |
Bando, Y | 1 |
Tsuji, A | 1 |
Morimoto, M | 1 |
Kobayashi, K | 1 |
Hyodo, I | 1 |
Jiang, Y | 1 |
Mason, M | 1 |
Cho, Y | 1 |
Chittiprolu, A | 1 |
Zhang, X | 1 |
Harden, K | 1 |
Gong, Y | 1 |
Harris, MR | 1 |
Barton, DL | 1 |
Ben Nasr, S | 1 |
Zribi, A | 1 |
Ben Hassen, M | 1 |
Doghri, Y | 1 |
Ben Abdallah, I | 1 |
Trigui, E | 1 |
Fendri, S | 1 |
Ayari, J | 1 |
Balti, M | 1 |
Haddaoui, A | 1 |
Hecht, JR | 1 |
Lonardi, S | 1 |
Bendell, J | 1 |
Sim, HW | 1 |
Macarulla, T | 2 |
Lopez, CD | 1 |
Van Cutsem, E | 3 |
Muñoz Martin, AJ | 1 |
Park, JO | 1 |
Greil, R | 1 |
Wang, H | 1 |
Hozak, RR | 1 |
Gueorguieva, I | 1 |
Lin, Y | 1 |
Rao, S | 1 |
Ryoo, BY | 1 |
Park, JJ | 1 |
Hajj, C | 1 |
Reyngold, M | 1 |
Shi, W | 1 |
Zhang, Z | 1 |
Cuaron, JJ | 1 |
Crane, CH | 3 |
O'Reilly, EM | 1 |
Lowery, MA | 1 |
Yu, KH | 1 |
Goodman, KA | 1 |
Wu, AJ | 1 |
Dougherty, JP | 2 |
Wolff, BS | 1 |
Cullen, MJ | 2 |
Saligan, LN | 1 |
Gershengorn, MC | 2 |
Chaoul, A | 1 |
Milbury, K | 1 |
Spelman, A | 1 |
Basen-Engquist, K | 1 |
Hall, MH | 1 |
Wei, Q | 1 |
Shih, YT | 1 |
Arun, B | 4 |
Valero, V | 4 |
Perkins, GH | 1 |
Babiera, GV | 1 |
Wangyal, T | 1 |
Engle, R | 1 |
Harrison, CA | 1 |
Li, Y | 1 |
Cohen, L | 2 |
de Castro Junior, G | 1 |
Segalla, JG | 1 |
de Azevedo, SJ | 1 |
Andrade, CJ | 1 |
Grabarz, D | 1 |
de Araújo Lima França, B | 1 |
Del Giglio, A | 1 |
Lazaretti, NS | 1 |
Álvares, MN | 1 |
Pedrini, JL | 1 |
Kussumoto, C | 1 |
de Matos Neto, JN | 1 |
Forones, NM | 1 |
Fernandes Júnior, HJ | 1 |
Borges, G | 1 |
Girotto, G | 1 |
da Silva, IDCG | 1 |
Maluf-Filho, F | 1 |
Skare, NG | 1 |
Tong, H | 1 |
Fan, Z | 1 |
Liu, B | 1 |
Lu, T | 1 |
Akin, S | 1 |
Kas Guner, C | 1 |
Fu, T | 1 |
Guang, HJ | 1 |
Gao, XZ | 1 |
Bachet, JB | 1 |
Lucidarme, O | 1 |
Levache, CB | 1 |
Barbier, E | 1 |
Raoul, JL | 1 |
Lecomte, T | 1 |
Desauw, C | 1 |
Brocard, F | 1 |
Pernot, S | 1 |
Breysacher, G | 1 |
Lagasse, JP | 1 |
Di Fiore, F | 1 |
Etienne, PL | 1 |
Dupuis, OJM | 1 |
Aleba, A | 1 |
Lepage, C | 1 |
Taieb, J | 1 |
Springer, DA | 1 |
Papneja, N | 1 |
Zaidi, A | 1 |
Chalchal, H | 1 |
Moser, M | 1 |
Tan, K | 1 |
Olson, C | 1 |
Haider, K | 1 |
Shaw, J | 1 |
Ahmed, S | 1 |
Schwartzberg, LS | 1 |
Tauer, KW | 1 |
Hermann, RC | 1 |
Makari-Judson, G | 1 |
Isaacs, C | 1 |
Beck, JT | 1 |
Kaklamani, V | 1 |
Stepanski, EJ | 1 |
Rugo, HS | 1 |
Wang, W | 1 |
Bell-McGuinn, K | 1 |
Kirshner, JJ | 1 |
Eisenberg, P | 1 |
Emanuelson, R | 1 |
Keaton, M | 1 |
Levine, E | 1 |
Medgyesy, DC | 1 |
Qamar, R | 1 |
Starr, A | 1 |
Ro, SK | 1 |
Lokker, NA | 1 |
Hudis, CA | 1 |
Deenen, MJ | 1 |
Dewit, L | 1 |
Boot, H | 1 |
Beijnen, JH | 1 |
Schellens, JH | 1 |
Cats, A | 1 |
Innominato, PF | 2 |
Giacchetti, S | 2 |
Moreau, T | 2 |
Bjarnason, GA | 1 |
Smaaland, R | 1 |
Focan, C | 1 |
Garufi, C | 1 |
Iacobelli, S | 1 |
Tampellini, M | 1 |
Tumolo, S | 1 |
Carvalho, C | 1 |
Karaboué, A | 2 |
Poncet, A | 1 |
Spiegel, D | 1 |
Lévi, F | 3 |
Curigliano, G | 1 |
Pivot, X | 1 |
Cortés, J | 1 |
Elias, A | 1 |
Cesari, R | 1 |
Khosravan, R | 2 |
Collier, M | 1 |
Huang, X | 1 |
Cataruozolo, PE | 1 |
Kern, KA | 1 |
Goldhirsch, A | 1 |
Rubovszky, G | 1 |
Láng, I | 1 |
Ganofszky, E | 1 |
Horváth, Z | 1 |
Juhos, E | 1 |
Nagy, T | 1 |
Szabó, E | 1 |
Szentirmay, Z | 1 |
Budai, B | 1 |
Hitre, E | 1 |
Saif, MW | 1 |
Kaley, K | 1 |
Brennan, M | 1 |
Garcon, MC | 1 |
Rodriguez, G | 1 |
Rodriguez, T | 1 |
Tabernero, J | 1 |
Lakomý, R | 1 |
Prausová, J | 1 |
Ruff, P | 2 |
van Hazel, GA | 1 |
Moiseyenko, VM | 1 |
Ferry, DR | 1 |
McKendrick, JJ | 1 |
Soussan-Lazard, K | 1 |
Chevalier, S | 1 |
Allegra, CJ | 2 |
Mahaseth, H | 1 |
Brutcher, E | 1 |
Kauh, J | 1 |
Hawk, N | 1 |
Kim, S | 1 |
Chen, Z | 1 |
Kooby, DA | 1 |
Maithel, SK | 1 |
Landry, J | 1 |
El-Rayes, BF | 1 |
Weymann, KB | 1 |
Wood, LJ | 1 |
Zhu, X | 1 |
Marks, DL | 1 |
Likhacheva, A | 1 |
Jhingran, A | 1 |
Bodurka, DC | 1 |
Sun, C | 1 |
Sam, M | 1 |
Eifel, PJ | 1 |
Hamaker, ME | 1 |
Seynaeve, C | 1 |
Wymenga, AN | 1 |
van Tinteren, H | 1 |
Nortier, JW | 1 |
Maartense, E | 1 |
de Graaf, H | 1 |
de Jongh, FE | 1 |
Braun, JJ | 1 |
Los, M | 1 |
Schrama, JG | 1 |
van Leeuwen-Stok, AE | 1 |
de Groot, SM | 1 |
Smorenburg, CH | 1 |
Meyer, T | 1 |
Qian, W | 1 |
Caplin, ME | 1 |
Armstrong, G | 1 |
Lao-Sirieix, SH | 1 |
Hardy, R | 1 |
Valle, JW | 1 |
Talbot, DC | 1 |
Cunningham, D | 4 |
Reed, N | 1 |
Shaw, A | 1 |
Navalkissoor, S | 1 |
Luong, TV | 1 |
Corrie, PG | 1 |
Ortiz-Tudela, E | 1 |
Iurisci, I | 1 |
Beau, J | 1 |
Rol, MA | 1 |
Madrid, JA | 1 |
Mahoney, SE | 2 |
Davis, JM | 2 |
Murphy, EA | 2 |
McClellan, JL | 2 |
Pena, MM | 2 |
Ratcliff, CG | 1 |
Lam, CY | 1 |
Roxburgh, P | 1 |
Lumsden, GR | 1 |
Paul, J | 1 |
Harden, S | 1 |
Sweeting, L | 1 |
James, A | 1 |
Crellin, A | 1 |
Morrison, R | 1 |
Evans, TR | 1 |
McDonald, AC | 1 |
Middleton, G | 1 |
Silcocks, P | 1 |
Cox, T | 1 |
Valle, J | 1 |
Wadsley, J | 1 |
Propper, D | 1 |
Coxon, F | 1 |
Ross, P | 1 |
Madhusudan, S | 1 |
Roques, T | 1 |
Falk, S | 2 |
Wadd, N | 1 |
Harrison, M | 1 |
Corrie, P | 1 |
Iveson, T | 1 |
Robinson, A | 1 |
McAdam, K | 1 |
Eatock, M | 1 |
Evans, J | 1 |
Archer, C | 1 |
Hickish, T | 1 |
Garcia-Alonso, A | 1 |
Nicolson, M | 1 |
Steward, W | 1 |
Anthoney, A | 1 |
Greenhalf, W | 1 |
Shaw, V | 1 |
Costello, E | 1 |
Naisbitt, D | 1 |
Rawcliffe, C | 1 |
Nanson, G | 1 |
Neoptolemos, J | 1 |
Miwa, K | 1 |
Oki, E | 2 |
Emi, Y | 2 |
Saeki, H | 2 |
Kusumoto, T | 2 |
Akagi, Y | 2 |
Ogata, Y | 2 |
Samura, H | 1 |
Tokunaga, S | 1 |
Ishikawa, H | 1 |
Tanaka, T | 2 |
Sueyoshi, S | 1 |
Higashi, H | 1 |
Matsuda, H | 1 |
Touyama, T | 2 |
Maehara, Y | 2 |
Shimokawa, M | 1 |
Sadanaga, N | 1 |
Kimura, M | 1 |
Baba, H | 1 |
Shirouzu, K | 1 |
Matsuda, C | 1 |
Honda, M | 1 |
Tanaka, C | 1 |
Fukunaga, M | 1 |
Ishibashi, K | 1 |
Munemoto, Y | 1 |
Hata, T | 1 |
Bando, H | 1 |
Oshiro, M | 1 |
Kobayashi, M | 1 |
Tokunaga, Y | 1 |
Fujii, A | 1 |
Nagata, N | 1 |
Oba, K | 1 |
Mishima, H | 1 |
Wang-Gillam, A | 2 |
Li, CP | 1 |
Bodoky, G | 1 |
Dean, A | 1 |
Shan, YS | 1 |
Jameson, G | 1 |
Lee, KH | 1 |
Blanc, JF | 1 |
Hubner, RA | 1 |
Chiu, CF | 1 |
Schwartsmann, G | 1 |
Siveke, JT | 1 |
Braiteh, F | 1 |
Moyo, V | 1 |
Belanger, B | 1 |
Dhindsa, N | 1 |
Bayever, E | 1 |
Von Hoff, DD | 1 |
Chen, LT | 1 |
Tebbutt, NC | 1 |
Price, TJ | 1 |
Ferraro, DA | 1 |
Wong, N | 1 |
Veillard, AS | 1 |
Hall, M | 1 |
Sjoquist, KM | 1 |
Pavlakis, N | 1 |
Strickland, A | 1 |
Varma, SC | 1 |
Cooray, P | 1 |
Young, R | 1 |
Underhill, C | 1 |
Shannon, JA | 1 |
Ganju, V | 1 |
Gebski, V | 1 |
Oh, PJ | 1 |
Lee, JR | 1 |
Vaudo, CE | 1 |
Gil, B | 1 |
Galuski, K | 1 |
Zarwan, C | 1 |
Nugent, FW | 1 |
Loibl, S | 1 |
von Minckwitz, G | 1 |
Harbeck, N | 1 |
Janni, W | 1 |
Elling, D | 1 |
Kaufmann, M | 1 |
Eggemann, H | 1 |
Nekljudova, V | 1 |
Sommer, H | 2 |
Kiechle, M | 1 |
Kümmel, S | 1 |
Sirohi, B | 1 |
Pluzanska, A | 1 |
Utracka-Hutka, B | 1 |
Zaluski, J | 1 |
Glynne-Jones, R | 1 |
Koralewski, P | 1 |
Bridgewater, J | 1 |
Mainwaring, P | 1 |
Wasan, H | 1 |
Wang, JY | 1 |
Szczylik, C | 1 |
Clingan, P | 1 |
Chan, RT | 1 |
Tabah-Fisch, I | 1 |
Cassidy, J | 2 |
Park, HC | 1 |
Janjan, NA | 2 |
Mendoza, TR | 3 |
Lin, EH | 1 |
Vadhan-Raj, S | 1 |
Hundal, M | 1 |
Zhang, Y | 1 |
Delclos, ME | 1 |
Das, P | 1 |
Wang, XS | 2 |
Cleeland, CS | 3 |
Krishnan, S | 1 |
Skof, E | 1 |
Rebersek, M | 1 |
Hlebanja, Z | 1 |
Ocvirk, J | 1 |
Yothers, G | 1 |
O'Connell, MJ | 1 |
Sharif, S | 1 |
Colangelo, LH | 1 |
Lopa, SH | 1 |
Petrelli, NJ | 1 |
Goldberg, RM | 2 |
Atkins, JN | 1 |
Seay, TE | 1 |
Fehrenbacher, L | 1 |
O'Reilly, S | 1 |
Chu, L | 1 |
Azar, CA | 1 |
Wolmark, N | 1 |
Degirmenci, M | 1 |
Karaca, B | 1 |
Gorumlu, G | 1 |
Durusoy, R | 1 |
Demir Piskin, G | 1 |
Bozkurt, MT | 1 |
Cirak, Y | 1 |
Tunali, D | 1 |
Karabulut, B | 1 |
Sanli, UA | 1 |
Uslu, R | 1 |
Jones, A | 1 |
O'Brien, M | 1 |
Nowara, E | 1 |
Welt, A | 1 |
Pienkowski, T | 1 |
Rolski, J | 1 |
Pham, ML | 1 |
Perraud, K | 1 |
Trillet-Lenoir, V | 1 |
Koukourakis, MI | 1 |
Giatromanolaki, A | 1 |
Pitiakoudis, M | 1 |
Kouklakis, G | 1 |
Tsoutsou, P | 1 |
Abatzoglou, I | 1 |
Panteliadou, M | 1 |
Sismanidou, K | 1 |
Sivridis, E | 1 |
Boulikas, T | 1 |
Zhang, J | 1 |
Lee, J | 1 |
Urba, S | 1 |
Foster, J | 1 |
Worden, F | 1 |
Hurmuzlu, M | 1 |
Aarstad, HJ | 1 |
Aarstad, AK | 1 |
Hjermstad, MJ | 1 |
Viste, A | 1 |
Sweeney, CJ | 1 |
Chiorean, EG | 2 |
Verschraegen, CF | 1 |
Lee, FC | 1 |
Jones, S | 1 |
Royce, M | 2 |
Tye, L | 1 |
Liau, KF | 1 |
Bello, A | 1 |
Chao, R | 1 |
Burris, HA | 1 |
Malik, I | 1 |
Bernal, P | 1 |
Byrd, J | 1 |
Gallerani, E | 1 |
Bauer, J | 1 |
Hess, D | 1 |
Boehm, S | 1 |
Droege, C | 1 |
Jeckelmann, S | 1 |
Miani, M | 1 |
Herrmann, R | 1 |
Marsoni, S | 1 |
Sperka, S | 1 |
Sessa, C | 1 |
Awada, A | 1 |
Gil, T | 1 |
Whenham, N | 1 |
Van Hamme, J | 1 |
Besse-Hammer, T | 1 |
Brendel, E | 1 |
Delesen, H | 1 |
Joosten, MC | 1 |
Lathia, CD | 1 |
Loembé, BA | 1 |
Piccart-Ghebart, M | 1 |
Hendlisz, A | 1 |
Welzel, G | 1 |
Hägele, V | 1 |
Wenz, F | 1 |
Mai, SK | 1 |
Satoh, T | 1 |
Yamada, Y | 1 |
Muro, K | 1 |
Hayashi, H | 1 |
Shimada, Y | 1 |
Takahari, D | 1 |
Taku, K | 1 |
Nakajima, TE | 1 |
Shi, X | 1 |
Brown, KH | 1 |
Boku, N | 2 |
Liu, L | 1 |
Rissling, M | 1 |
Natarajan, L | 1 |
Fiorentino, L | 1 |
Mills, PJ | 1 |
Dimsdale, JE | 1 |
Sadler, GR | 1 |
Parker, BA | 1 |
Ancoli-Israel, S | 1 |
Chang, KJ | 1 |
Reid, T | 1 |
Senzer, N | 1 |
Swisher, S | 1 |
Pinto, H | 1 |
Hanna, N | 1 |
Chak, A | 1 |
Soetikno, R | 1 |
Sanghani, S | 1 |
Schiel, MA | 1 |
Yu, M | 1 |
Burns, M | 1 |
Tong, Y | 1 |
Hinkle, DT | 1 |
Coleman, N | 1 |
Robb, B | 1 |
LeBlanc, J | 1 |
Clark, R | 1 |
Bufill, J | 1 |
Curie, C | 1 |
Loehrer, PJ | 1 |
Cardenes, H | 1 |
Leong, S | 1 |
Eckhardt, SG | 1 |
Chan, E | 1 |
Messersmith, WA | 1 |
Spratlin, J | 1 |
Camidge, DR | 1 |
Diab, S | 1 |
Lin, X | 2 |
Chow Maneval, E | 1 |
Lockhart, AC | 2 |
Karachaliou, N | 1 |
Ziras, N | 1 |
Syrigos, K | 1 |
Tryfonidis, K | 1 |
Papadimitraki, E | 1 |
Kontopodis, E | 1 |
Bozionelou, V | 1 |
Kalykaki, A | 1 |
Georgoulias, V | 1 |
Mavroudis, D | 1 |
Qi, WX | 1 |
Tang, LN | 1 |
He, AN | 1 |
Shen, Z | 1 |
Yao, Y | 1 |
Peddi, PF | 1 |
Lubner, S | 1 |
McWilliams, R | 1 |
Tan, BR | 1 |
Picus, J | 1 |
Sorscher, SM | 1 |
Suresh, R | 1 |
Wang, J | 1 |
Menias, C | 1 |
Gao, F | 1 |
Linehan, D | 1 |
Gordon, B | 1 |
Parameswaran, R | 1 |
Titcomb, DR | 1 |
Blencowe, NS | 1 |
Berrisford, RG | 1 |
Wajed, SA | 1 |
Streets, CG | 1 |
Hollowood, AD | 1 |
Krysztopik, R | 1 |
Barham, CP | 1 |
Blazeby, JM | 1 |
Ducreux, M | 1 |
Adenis, A | 1 |
Pignon, JP | 1 |
François, E | 1 |
Chauffert, B | 1 |
Ichanté, JL | 1 |
Boucher, E | 1 |
Ychou, M | 1 |
Pierga, JY | 1 |
Montoto-Grillot, C | 1 |
Conroy, T | 1 |
Carrato, A | 1 |
Swieboda-Sadlej, A | 1 |
Staszewska-Skurczynska, M | 1 |
Lim, R | 1 |
Roman, L | 1 |
Shparyk, Y | 1 |
Bondarenko, I | 1 |
Jonker, DJ | 1 |
Sun, Y | 1 |
De la Cruz, JA | 1 |
Williams, JA | 1 |
Korytowsky, B | 1 |
Christensen, JG | 1 |
Tursi, JM | 1 |
Lechuga, MJ | 1 |
Osterlund, P | 1 |
Orpana, A | 1 |
Elomaa, I | 1 |
Repo, H | 1 |
Joensuu, H | 1 |
Kaufmann, SH | 1 |
Atherton, P | 1 |
Sloan, JA | 1 |
Adjei, AA | 1 |
Pitot, HC | 1 |
Alberts, SR | 1 |
Rubin, J | 1 |
Miller, LL | 1 |
Erlichman, C | 1 |
Fleming, GF | 1 |
Schilsky, RL | 2 |
Schumm, LP | 1 |
Meyerson, A | 1 |
Hong, AM | 1 |
Vogelzang, NJ | 2 |
Ratain, MJ | 3 |
Gourley, C | 1 |
Edwards, C | 2 |
Samuel, L | 1 |
Bisset, D | 1 |
Camboni, G | 1 |
Young, A | 1 |
Boyle, D | 1 |
Jodrell, D | 1 |
Pusztai, L | 1 |
Reuben, JM | 1 |
Martinez, MM | 1 |
Willey, JS | 1 |
Lara, J | 1 |
Syed, A | 1 |
Fritsche, HA | 1 |
Bruera, E | 1 |
Booser, D | 1 |
Ibrahim, N | 1 |
Rivera, E | 2 |
Hortobagyi, GN | 2 |
Kumar, N | 1 |
Allen, KA | 1 |
Riccardi, D | 1 |
Bercu, BB | 1 |
Cantor, A | 1 |
Minton, S | 1 |
Balducci, L | 1 |
Jacobsen, PB | 1 |
de Jong, N | 3 |
Candel, MJ | 2 |
Schouten, HC | 3 |
Abu-Saad, HH | 3 |
Courtens, AM | 3 |
Kuehr, T | 1 |
Rapoport, BL | 1 |
Daniel, F | 1 |
Jacobs, C | 1 |
Davidson, N | 1 |
Thaler, J | 1 |
Boussard, B | 1 |
Carmichael, J | 1 |
Poh, SB | 1 |
Bai, LY | 1 |
Chen, PM | 1 |
Kim, JS | 2 |
Cho, MJ | 1 |
Yoon, WH | 1 |
Song, KS | 1 |
Sharma, R | 1 |
Rivory, L | 1 |
Beale, P | 1 |
Ong, S | 1 |
Horvath, L | 1 |
Clarke, SJ | 1 |
Meyers, C | 1 |
Groves, M | 1 |
Francis, D | 1 |
Broglio, K | 1 |
Yin, G | 1 |
Buchholz, T | 1 |
Hofheinz, RD | 1 |
Kubicka, S | 1 |
Wollert, J | 1 |
Arnold, D | 1 |
Hochhaus, A | 1 |
Pentheroudakis, G | 1 |
Pappas, P | 1 |
Golfinopoulos, V | 1 |
Fountzilas, G | 1 |
Nikolaidou, M | 1 |
Boumba, VA | 1 |
Vougiouklakis, T | 1 |
Nikiforidis, L | 1 |
Tzamakou, E | 1 |
Siarabi, O | 1 |
Marselos, M | 1 |
Pavlidis, N | 1 |
Wang, XX | 1 |
Zhou, ZM | 1 |
Yuan, ZY | 1 |
Zhang, DS | 1 |
Shi, YX | 1 |
Jiang, WQ | 1 |
Miyake, Y | 1 |
Iwasaki, Y | 1 |
Shiraha, H | 1 |
Sakaguchi, K | 1 |
Shiratori, Y | 1 |
Czito, BG | 1 |
Bendell, JC | 1 |
Willett, CG | 1 |
Morse, MA | 1 |
Blobe, GC | 1 |
Tyler, DS | 1 |
Thomas, J | 1 |
Ludwig, KA | 1 |
Mantyh, CR | 1 |
Ashton, J | 1 |
Yu, D | 1 |
Hurwitz, HI | 1 |
Shitara, K | 1 |
Munakata, M | 1 |
Muto, O | 1 |
Kasai, M | 1 |
Okada, R | 1 |
Mitobe, S | 1 |
Sakata, Y | 1 |
Yoshino, T | 1 |
Onozawa, Y | 1 |
Hironaka, S | 1 |
Fukutomi, A | 1 |
Yamaguchi, Y | 1 |
Hasuike, N | 1 |
Yamazaki, K | 1 |
Machida, N | 1 |
Ono, H | 1 |
Zachariae, R | 1 |
Paulsen, K | 1 |
Mehlsen, M | 1 |
Jensen, AB | 1 |
Johansson, A | 1 |
von der Maase, H | 1 |
Kester, AD | 1 |
Traina, TA | 1 |
Theodoulou, M | 1 |
Feigin, K | 1 |
Patil, S | 1 |
Tan, KL | 1 |
Dugan, U | 1 |
Norton, L | 1 |
Hudis, C | 1 |
Van Dam, FS | 2 |
Linssen, AC | 1 |
Engelsman, E | 1 |
van Benthem, J | 1 |
Hanewald, GJ | 1 |
John, WJ | 1 |
Neefe, JR | 1 |
Macdonald, JS | 1 |
Cantrell, J | 1 |
Smith, M | 1 |
Johnson, DH | 1 |
Paul, D | 1 |
Hande, KR | 1 |
Sanz-Altamira, PM | 1 |
Spence, LD | 1 |
Huberman, MS | 1 |
Posner, MR | 1 |
Steele, G | 1 |
Perry, LJ | 1 |
Stuart, KE | 1 |
Chen, JS | 1 |
Jan, YY | 1 |
Lin, YC | 1 |
Wang, HM | 1 |
Chang, WC | 1 |
Liau, CT | 1 |
Muggia, FM | 1 |
Wu, X | 1 |
Spicer, D | 1 |
Groshen, S | 1 |
Jeffers, S | 1 |
Leichman, CG | 1 |
Leichman, L | 1 |
Chan, KK | 1 |
Marshall, JL | 1 |
Richmond, E | 1 |
DeLap, RJ | 1 |
Dikken, C | 1 |
Sitzia, J | 1 |
Soori, GS | 1 |
Oldham, RK | 1 |
Dobbs, TW | 1 |
Bury, MJ | 1 |
Church, CK | 1 |
DePriest, C | 1 |
Mormont, MC | 1 |
Waterhouse, J | 1 |
Bleuzen, P | 1 |
Jami, A | 1 |
Bogdan, A | 1 |
Lellouch, J | 1 |
Misset, JL | 1 |
Touitou, Y | 1 |
Domenge, C | 1 |
Hill, C | 1 |
Lefebvre, JL | 1 |
De Raucourt, D | 1 |
Rhein, B | 1 |
Wibault, P | 1 |
Marandas, P | 1 |
Coche-Dequeant, B | 1 |
Stromboni-Luboinski, M | 1 |
Sancho-Garnier, H | 1 |
Luboinski, B | 1 |
Cascinu, S | 1 |
Graziano, F | 1 |
Barni, S | 1 |
Labianca, R | 1 |
Comella, G | 1 |
Casaretti, R | 1 |
Frontini, L | 1 |
Catalano, V | 1 |
Baldelli, AM | 1 |
Catalano, G | 1 |
Schwartz, AL | 1 |
Mori, M | 1 |
Gao, R | 1 |
Nail, LM | 1 |
King, ME | 1 |
Olencki, T | 1 |
Peereboom, D | 1 |
Wood, L | 1 |
Budd, GT | 1 |
Novick, A | 1 |
Finke, J | 1 |
McLain, D | 1 |
Elson, P | 1 |
Bukowski, RM | 1 |
Schagen, SB | 1 |
Hamburger, HL | 1 |
Muller, MJ | 1 |
Boogerd, W | 1 |
Cyjon, A | 1 |
Neuman-Levin, M | 1 |
Rakowsky, E | 1 |
Greif, F | 1 |
Belinky, A | 1 |
Atar, E | 1 |
Hardoff, R | 1 |
Brenner, B | 1 |
Sulkes, A | 1 |
Guo, H | 1 |
Johnson, BA | 1 |
Engstrom, MC | 1 |
Patt, YZ | 1 |
Hassan, MM | 1 |
Lozano, RD | 1 |
Waugh, KA | 1 |
Hoque, AM | 1 |
Frome, AI | 1 |
Lahoti, S | 1 |
Ellis, L | 1 |
Vauthey, JN | 1 |
Curley, SA | 1 |
Schnirer, II | 1 |
Raijman, I | 1 |
Mani, S | 2 |
Bertucci, D | 1 |
Stadler, WM | 1 |
Rudin, CM | 1 |
Kunkel, K | 1 |
Holmlund, JT | 1 |
Geary, RS | 1 |
Kindler, HL | 1 |
Dorr, FA | 1 |
Evans, WK | 1 |
Wierzbicki, R | 1 |
Shepherd, FA | 1 |
Rusthoven, J | 1 |
Stewart, DJ | 1 |
Aitken, SE | 1 |
Maroun, JA | 1 |
Ezzat, A | 1 |
Saeki, T | 1 |
Jinushi, K | 1 |
Kim, R | 1 |
Toi, M | 1 |
Saeki, K | 1 |
Yoshinaka, K | 1 |
Yanagawa, E | 1 |
Niimoto, M | 1 |
Hattori, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen[NCT02923921] | Phase 3 | 567 participants (Actual) | Interventional | 2017-03-01 | Completed | ||
Developing and Examining Preliminary Effects of An Innovative Care-improvement Smartphone-based Perioperative Solution for Women Undergoing Breast Cancer Surgery (iCareBreast): A Pilot Randomized Controlled Trial[NCT04172350] | 112 participants (Anticipated) | Interventional | 2019-11-19 | Recruiting | |||
A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer[NCT01249352] | Phase 2/Phase 3 | 104 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment[NCT05576545] | 73 participants (Actual) | Interventional | 2020-09-18 | Completed | |||
Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis[NCT01674309] | Phase 2 | 65 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy[NCT00493636] | Phase 2 | 160 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer[NCT00246571] | Phase 2 | 217 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients[NCT02829385] | Phase 2 | 53 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470] | Phase 3 | 1,226 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802] | 190 participants (Anticipated) | Observational | 2016-10-06 | Recruiting | |||
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-11-21 | Recruiting | ||
Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2021-06-15 | Active, not recruiting | ||
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857] | Phase 1/Phase 2 | 45 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers[NCT06135896] | Phase 2 | 98 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | ||
Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508] | Phase 2 | 178 participants (Actual) | Interventional | 2018-09-04 | Completed | ||
Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480] | Phase 2 | 0 participants | Interventional | Completed | |||
A Phase II Trial of Preoperative Capecitabine Plus Irinotecan Followed by Combined Modality Capecitabine and Radiation for Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53[NCT00216086] | Phase 2 | 22 participants (Actual) | Interventional | 2005-05-31 | Terminated (stopped due to Funding withdrawn) | ||
Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment[NCT00457691] | Phase 3 | 768 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment, A Pilot Study[NCT00387062] | Phase 1 | 50 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529] | Phase 2/Phase 3 | 63 participants (Actual) | Interventional | 2011-01-12 | Completed | ||
Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study[NCT00842686] | Phase 2 | 60 participants (Anticipated) | Interventional | 2009-01-31 | Active, not recruiting | ||
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study[NCT02007148] | Phase 2 | 51 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | ||
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer[NCT03045575] | 65 participants (Actual) | Observational | 2016-08-02 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. (NCT02923921)
Timeframe: Randomization to Progressive Disease (PD) or Date of Death (Up To 30 Months)
Intervention | Months (Median) |
---|---|
Pegilodecakin + FOLFOX | 4.99 |
FOLFOX | 5.17 |
Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date. (NCT02923921)
Timeframe: Randomization to date of death from any cause (Up To 30 Months)
Intervention | Months (Median) |
---|---|
Pegilodecakin + FOLFOX | 5.78 |
FOLFOX | 6.28 |
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants who discontinued study treatment (for reasons other than progression) before entering concurrent phase were considered to have non-evaluable response. (NCT02923921)
Timeframe: Randomization to PD (Up To 30 Months)
Intervention | Percentage of participants (Number) |
---|---|
Pegilodecakin + FOLFOX | 4.6 |
FOLFOX | 5.6 |
The 12-month survival rate is defined as the percentage of participants who have not died 12 months after the date of randomization. (NCT02923921)
Timeframe: From randomization to until the date of first documented date of death from any cause within 12 months
Intervention | Percentage of participants (Number) |
---|---|
Pegilodecakin + FOLFOX | 14.7 |
FOLFOX | 19.1 |
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. (NCT02923921)
Timeframe: Randomization to Objective Progressive Disease or Start of New Anti-Cancer Therapy (Up To 30 Months)
Intervention | Percentage of participants (Number) |
---|---|
Pegilodecakin + FOLFOX | 42.8 |
FOLFOX | 36.6 |
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant did not have a complete baseline disease assessment, then PFS was censored at the enrollment date, regardless whether or not objectively determined PD or death had been observed for the participant. (NCT02923921)
Timeframe: Randomization to Progressive Disease (PD) or Date of Death (Up To 30 Months)
Intervention | Months (Median) |
---|---|
Pegilodecakin + FOLFOX | 2.14 |
FOLFOX | 2.10 |
Duration of overall response was calculated as the time (days) from first documentation of CR or PR (whichever status is recorded first) until the first date that recurrent or progressive disease (PD) or death is objectively documented. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: Period measured from the first documentation of complete or partial response (whichever status is recorded first) until the first date that recurrent or progressive disease or death is objectively documented.
Intervention | Days (Median) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 94 |
B (Placebo + Gemcitabine or Capecitabine) | 147 |
Overall response rate was defined as the proportion of participants experiencing complete response (CR) and partial response (PR) as best overall response. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: The overall tumor burden at baseline will be compared with subsequent measurements up to the date of first documented disease progression or the date of death due to any cause, if before progression, assessed up to 39 months.
Intervention | percentage of participants (Number) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 19.8 |
B (Placebo + Gemcitabine or Capecitabine) | 12.7 |
(NCT00493636)
Timeframe: From the date of randomization to date of death due to any cause, assessed up to 56 months.
Intervention | Days (Median) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 407 |
B (Placebo + Gemcitabine or Capecitabine) | 348 |
(NCT00493636)
Timeframe: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months.
Intervention | Days (Median) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 103 |
B (Placebo + Gemcitabine or Capecitabine) | 81 |
(NCT00493636)
Timeframe: Calculated as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical, whichever is earlier), assessed up to 39 months.
Intervention | Days (Median) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 111 |
B (Placebo + Gemcitabine or Capecitabine) | 82 |
Time in months from the date of randomization to date of death due to any cause. OS was calculated as (date of death minus randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
Intervention | months (Median) |
---|---|
Sunitinib | 9.4 |
Standard of Care | 10.5 |
Probability that the participants will survive at end of 1 year from the first dose of study treatment. Calculated using data collected from baseline until death (up to 3 years after first dose of study medication). Probability calculated from Kaplan-Meier estimate. (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
Intervention | ratio (Number) |
---|---|
Sunitinib | 0.376 |
Standard of Care | 0.446 |
Blood samples were collected to enumerate the number of total CECs and sVEGFR1, sVEGFR2 and sVEGFR3 protein expression and/or cellular viability. (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
Intervention | cells/mL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Cycle 1, Day 1 (n=42, 48) | Cycle 1, Day 15 (n=28, 37) | Cycle 2, Day 1 (n=33, 35) | Cycle 2, Day 15 (n=7, 5) | Cycle 3, Day 1 (n=27, 25) | Cycle 3, Day 15 (n=4, 1) | Cycle 4, Day 1 (n=3, 5) | Cycle 5, Day 1 (n=2, 2) | EOT (n=18, 18) | |
Standard of Care | 1176.92 | 1199.32 | 1048.31 | 852.96 | 509.75 | 231.80 | 976.79 | 2031.67 | 1087.94 |
Sunitinib | 944.67 | 630 | 512.39 | 1310.86 | 390.09 | 923.85 | 169.24 | 145.68 | 477.83 |
Blood samples were collected to enumerate the number of total CTCs and insulin growth factor 1R positive (IGF-1R+) CTCs (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
Intervention | cells/7.5 mL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Cycle 1, Day 1 (n=33, 28) | Cycle 1, Day 15 (n=20, 16) | Cycle 2, Day 1 (n=19, 17) | Cycle 2, Day 15 (n=3, 7) | Cycle 3, Day 1 (n=8, 15) | Cycle 3, Day 15 (n=2, 4) | Cycle 4, Day 1 (n=2, 5) | Cycle 5, Day 1 (n=2, 3) | EOT (n=17,4) | |
Standard of Care | 17.71 | 10.69 | 3.18 | 0.86 | 10.60 | 0 | 0.60 | 0.33 | 3 |
Sunitinib | 119.76 | 183.60 | 189 | 33.33 | 36.50 | 40.50 | 61 | 19.50 | 55 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
Intervention | ng/mL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
Sunitinib | 0.02 | 29.4 | 32.3 | 33.4 | 28.5 | 40.4 | 30.9 | 36.1 | 21.3 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
Intervention | ng/mL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
Sunitinib | 0.14 | 94.9 | 94.4 | 91.6 | 78.6 | 105 | 82.2 | 84.2 | 63.6 |
Ctrough = plasma concentration of SU012662 prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
Intervention | ng/mL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
Sunitinib | NA | 29.9 | 37.2 | 37.3 | 39.8 | 40.1 | 38.7 | 41.9 | 28.6 |
Ctrough = plasma concentration of sunitinib prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
Intervention | ng/mL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
Sunitinib | NA | 67.5 | 73.4 | 69.8 | 69.3 | 65.3 | 68.7 | 58.4 | 64.0 |
Ctrough = plasma concentration of total drug (Sunitinib + SU012662) prior to study drug administration dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
Intervention | ng/mL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
Sunitinib | NA | 97.4 | 111 | 107 | 109 | 105 | 107 | 100 | 92.5 |
Time in months from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00246571)
Timeframe: Time from first response to disease progression up to 3 years from first dose
Intervention | months (Median) | |
---|---|---|
Core radiology assessment (n=3,7) | Investigator's assessment (n=10,12) | |
Standard of Care | NA | 4.6 |
Sunitinib | 3.0 | 3.6 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
Intervention | ng/mL (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
Sunitinib | 0.12 | 65.53 | 62.09 | 58.20 | 50.03 | 64.61 | 51.25 | 48.07 | 42.23 |
Plasma concentrations of sKIT were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
Intervention | pg/mL (Mean) | ||||||
---|---|---|---|---|---|---|---|
Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=49, 35) | Cycle 4 Day 1 (n=33, 27) | Cycle 5 Day 1 (n=28, 19) | Cycle 7 Day 1 (n=9, 8) | End Of Treatment (n=49, 11) | |
Standard of Care | 62232.81 | 65843.75 | 63582.86 | 62885.19 | 54811.05 | 56237.50 | 72854.55 |
Sunitinib | 61862.65 | 44987.88 | 30855.10 | 25887.88 | 21696.07 | 18166.67 | 25004.08 |
Plasma concentrations of sPlGF were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
Intervention | pg/mL (Mean) | ||||||
---|---|---|---|---|---|---|---|
Cycle 1 Day 1 (n=15, 11) | Cycle 2 Day 1 (n=11, 9) | Cycle 3 Day 1 (n=5, 4) | Cycle 4 Day 1 (n=2, 3) | Cycle 5 Day 1 (n=1, 3) | Cycle 7 Day 1 (n=1, 1) | End Of Treatment (n=5, 0) | |
Standard of Care | 37.23 | 36.24 | 40.08 | 33.23 | 51.83 | 38.50 | 0 |
Sunitinib | 36.96 | 168.05 | 72.16 | 144.60 | 118.30 | 176.60 | 87.54 |
Plasma concentrations of sVEGF-A were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
Intervention | pg/mL (Mean) | ||||||
---|---|---|---|---|---|---|---|
Cycle 1 Day 1 (n=83, 66) | Cycle 2 Day 1 (n=67, 50) | Cycle 3 Day 1 (n=49, 37) | Cycle 4 Day 1 (n=33, 28) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 10) | End Of Treatment (n=49, 12) | |
Standard of Care | 151.49 | 170.43 | 129.31 | 129.88 | 126.97 | 115.58 | 94.76 |
Sunitinib | 152.28 | 455.17 | 265.56 | 274.94 | 324.09 | 241.78 | 294.66 |
Plasma concentrations of sVEGFR3 were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
Intervention | pg/mL (Mean) | ||||||
---|---|---|---|---|---|---|---|
Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=48, 35) | Cycle 4 Day 1 (n=32, 27) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 9) | End Of Treatment (n=48, 10) | |
Standard of Care | 25857.19 | 24515.83 | 29034.86 | 27929.63 | 32949 | 32004.44 | 29194 |
Sunitinib | 24124.82 | 16299.70 | 14459.38 | 13702.81 | 16345.36 | 24795.56 | 26746.46 |
"Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause. PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death)." (NCT00246571)
Timeframe: Baseline, every 6 weeks until disease progression or death (up to 3 years from first dose)
Intervention | Months (Median) | |
---|---|---|
Core radiology laboratory assessment | Investigator's assessment | |
Standard of Care | 2.7 | 2.5 |
Sunitinib | 2.0 | 1.7 |
Objective response based assessment of confirmed response (CR) or confirmed partial response (PR) according to RECIST. CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with a greater than or equal to (≥) 30% decrease in the sum of the longest dimensions (SLD) of the target lesions taking as a reference the baseline SLD. (NCT00246571)
Timeframe: Baseline until response or disease progression (up to 3 years from first dose)
Intervention | percentage of participants (Number) | |
---|---|---|
Core radiology laboratory assessment | Investigator's assessment | |
Standard of Care | 6.7 | 11.5 |
Sunitinib | 2.7 | 8.8 |
"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)
Intervention | percentage of participants (Number) |
---|---|
Placebo/FOLFIRI | 11.1 |
Aflibercept/FOLFIRI | 19.8 |
"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
Intervention | months (Median) |
---|---|
Placebo/FOLFIRI | 12.06 |
Aflibercept/FOLFIRI | 13.50 |
"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)
Intervention | months (Median) |
---|---|
Placebo/FOLFIRI | 4.67 |
Aflibercept/FOLFIRI | 6.90 |
Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo
Intervention | participants (Number) | |
---|---|---|
At least one positive sample in the ADA assay | At least one positive sample in the NAb assay | |
Aflibercept/FOLFIRI | 8 | 1 |
Placebo/FOLFIRI | 18 | 2 |
"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
Intervention | participants (Number) | |||
---|---|---|---|---|
Treatment-Emergent Adverse Event (TEAE) | Serious TEAE | TEAE leading to Death | TEAE causing permanent treatment discontinuation | |
Aflibercept/FOLFIRI | 606 | 294 | 37 | 164 |
Placebo/FOLFIRI | 592 | 198 | 29 | 73 |
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
Intervention | percentage with confirmed response (Number) |
---|---|
MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
Intervention | months (Median) |
---|---|
MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
Intervention | percentage of participants with CBR (Number) |
---|---|
MM-398 Arm A (Mono Therapy Comparison) | 14 |
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
Intervention | percent of participants with TMR (Number) |
---|---|
MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
Intervention | months (Median) |
---|---|
MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
Intervention | months (Median) |
---|---|
MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
---|---|---|---|---|
Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
The three year rate of Disease-Free Survival (NCT00216086)
Timeframe: 36 months
Intervention | percentage (Number) |
---|---|
Single Group Assignment | 75.5 |
To determine the rates of local and distant disease recurrence after treatment. (NCT00216086)
Timeframe: 36 months
Intervention | percentage of particpants (Number) | |
---|---|---|
metastatic disease recurrence | locally recurrence | |
Single Group Assignment | 22 | 0 |
"· To determine the pathological response rate of preoperative chemotherapy with capecitabine and irinotecan followed by combined modality chemoradiation with capecitabine in patients with locally advanced rectal cancer.~Pathological response was defined in the protocol as the proportion of complete (pCR) and non-complete pathological response (pNCR) among all evaluable patients." (NCT00216086)
Timeframe: 36 months
Intervention | percentage of patients (Number) | |
---|---|---|
pCR | pNCR | |
Single Group Assignment | 33 | 56 |
DR was defined as the time from the first objective documentation of CR or PR that was subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
Intervention | Weeks (Median) |
---|---|
FOLFIRI + Sunitinib | 30.1 |
FOLFIRI + Placebo | 39.0 |
Objective disease response: participants with a confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
Intervention | Participants (Number) |
---|---|
FOLFIRI + Sunitinib | 124 |
FOLFIRI + Placebo | 128 |
OS was defined as the time from randomization to the date of death due to any cause. OS data were censored on the day following the date of the last contact at which the patient was known to be alive. (NCT00457691)
Timeframe: Baseline up to 30 months
Intervention | Weeks (Median) |
---|---|
FOLFIRI + Sunitinib | 87.9 |
FOLFIRI + Placebo | 85.9 |
PFS defined as time from date of randomization to date of first documentation of objective tumour progression or death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: First dose of study treatment up to 30 months
Intervention | Weeks (Median) |
---|---|
FOLFIRI + Sunitinib | 33.6 |
FOLFIRI + Placebo | 36.6 |
"EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problem); 3 indicates worst health state (eg, confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed and results in total score range -1.11 to 1.000; higher score indicates better health state." (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
Intervention | Scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
FOLFIRI + Placebo | 0.04 | 0.04 | 0.03 | 0.05 | 0.05 | 0.09 |
FOLFIRI + Sunitinib | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | 0.01 |
EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
Intervention | Scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
FOLFIRI + Placebo | 3.3 | 4.3 | 6.6 | 4.3 | 4.0 | 9.0 |
FOLFIRI + Sunitinib | 1.0 | 1.7 | 1.8 | 3.8 | -0.9 | -1.6 |
Symptom Interference score is comprised of the sum 6 function items from MDASI core (general activity, walking, work, mood, relations with other people, and enjoyment of life). Participant asked to rate how much symptoms have interfered in past 24 hours; each item rated from 0 to 10, with 0=did not interfere and 10=interfered completely; lower scores indicated better outcome (range: 0 to 60). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
Intervention | scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
FOLFIRI + Placebo | -1.3 | -1.7 | -1.2 | -0.2 | -1.7 | -1.0 |
FOLFIRI + Sunitinib | 0.0 | -0.1 | 0.2 | -0.5 | 2.1 | 3.1 |
Symptom Intensity score is comprised of the sum of 13 MDASI core items (ie, pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling). Participant asked to rate severity of each symptom at their worst in past 24 hours; each item rated from 0 to 10, with 0=symptom not present and 10=as bad as you can imagine; lower scores indicated better outcome (range: 0 to 130). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until end of treatment (EOT)/withdrawal
Intervention | Scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
FOLFIRI + Placebo | 0.4 | 0.9 | 1.8 | 2.7 | 1.2 | -2.7 |
FOLFIRI + Sunitinib | 1.7 | 0.8 | 1.0 | 0.7 | 0.8 | 5.0 |
4 reviews available for fluorouracil and Lassitude
Article | Year |
---|---|
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Fluorouracil; Humans | 2018 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2008 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2013 |
71 trials available for fluorouracil and Lassitude
Article | Year |
---|---|
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Docetaxel; Fatigue; Fluorourac | 2022 |
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neopla | 2022 |
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2021 |
Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.
Topics: Actigraphy; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2018 |
A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2018 |
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2018 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, A | 2013 |
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Breast | 2014 |
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine | 2014 |
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; De | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; | 2014 |
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2016 |
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Be | 2016 |
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Diseas | 2009 |
Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.
Topics: Activities of Daily Living; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidin | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas | 2009 |
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; B | 2010 |
Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deo | 2010 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dia | 2011 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2011 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian Peopl | 2012 |
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiot | 2012 |
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Do | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2012 |
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2012 |
Assessment and comparison of recovery after open and minimally invasive esophagectomy for cancer: an exploratory study in two centers.
Topics: Activities of Daily Living; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemoth | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrh | 2002 |
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bilirubin; Creatinine; Dose-Response Relationship, Dru | 2003 |
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fatigu | 2004 |
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Blood; | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2004 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2006 |
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2006 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Respo | 2006 |
Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 2007 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2007 |
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2007 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Colonic Neoplasms; Drug Admin | 1993 |
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatigue; Female; Fluo | 1997 |
Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.
Topics: Abdominal Pain; Adult; Aged; Alkaline Phosphatase; Angiography; Antimetabolites, Antineoplastic; Ant | 1997 |
Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.
Topics: Aged; Anorexia; Antidotes; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Bone Marrow; Di | 1998 |
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor | 1996 |
Chemo-biotherapy with 5-fluorouracil, leucovorin, and alpha interferon in metastatic carcinoma of the colon--a Cancer Biotherapy Research Group [CBRG] phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2000 |
Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colorectal Neoplasms; | 2000 |
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2000 |
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2001 |
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chills; Combined Moda | 2001 |
Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function.
Topics: Alpha Rhythm; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Carboplatin | 2001 |
Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug R | 2001 |
Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; DNA, Antise | 2002 |
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
36 other studies available for fluorouracil and Lassitude
Article | Year |
---|---|
Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Drug-R | 2022 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases | 2021 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Anima | 2017 |
Investigation of the relationship among fatigue, self-efficacy and quality of life during chemotherapy in patients with breast, lung or gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Percutaneous nerve electrical stimulation for fatigue caused by chemotherapy for cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fat | 2018 |
Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays.
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Behavior, Animal; Body Weight; Centr | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community He | 2019 |
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Campto | 2013 |
A role for orexin in cytotoxic chemotherapy-induced fatigue.
Topics: Animals; Antineoplastic Agents; Brain Stem; Cyclophosphamide; Cytotoxins; Doxorubicin; Drug Combinat | 2014 |
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Anxiety; Carcinoma; Chemoradiotherapy; Cispl | 2013 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circad | 2014 |
Dietary quercetin reduces chemotherapy-induced fatigue in mice.
Topics: Anemia; Animals; Antimetabolites, Antineoplastic; Chemokine CCL2; Dietary Supplements; Disease Model | 2014 |
Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer.
Topics: Adult; Affect; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; | 2014 |
[Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Anxiety; Camptothecin; Cognitive Dysfunction; Depression | 2016 |
Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Anus Neoplasms; Dihydrouracil Dehydrogen | 2016 |
Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fract | 2011 |
Quality of life outcomes in patients with anal cancer after combined radiochemotherapy.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Anus Neoplasms; Chemotherapy, Adjuvant; | 2011 |
The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy.
Topics: Actigraphy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studie | 2012 |
Effects of 5-fluorouracil chemotherapy on fatigue: role of MCP-1.
Topics: Anemia; Animals; Antimetabolites, Antineoplastic; Chemokine CCL2; Dose-Response Relationship, Drug; | 2013 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit?
Topics: Adult; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 2004 |
Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2004 |
Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognition Disorders; | 2005 |
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2007 |
Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Adm | 2007 |
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2007 |
Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arousal; Autonomic Nervous Sys | 2007 |
[Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cli | 2007 |
Life with cytostatic drugs.
Topics: Activities of Daily Living; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; | 1980 |
Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as | 1996 |
Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Di | 1998 |
Fatigue during preoperative chemoradiation for resectable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fatigue; Female; Fluorourac | 2001 |
[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Sche | 1989 |